Option chain shows key data for Medicus Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Medicus Pharma.

Medicus Pharma (NASDAQ:MDCX) Stock, Option Chain

Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Medicus Pharma Ltd

Medicus Pharma Ltd. - Warrant

Benchmark analyst Mike Hickey maintains Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) with a Buy and raises the price target from $12 to $14.

News

Price Target

Analyst Ratings

Benchmark Maintains Buy on Rush Street Interactive, Raises Price Target to $14

Guggenheim analyst Howard Ma maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Buy and raises the price target from $130 to $136.

ESTC

Guggenheim Maintains Buy on Elastic, Raises Price Target to $136

Guggenheim analyst Shahriar Pourreza maintains FirstEnergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) with a Buy and lowers the price target from $52 to $45.

Guggenheim Maintains Buy on FirstEnergy, Lowers Price Target to $45

Macro Economic Events

Market Summary

Bonds

Economics

Markets

General

NVDA

Benzinga Market Summary: Jan. PCE Price Index Comes In Line With Estimates, NVIDIA Rebounds, 10-Year Falls

Guggenheim analyst John Heinbockel maintains Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) with a Buy and raises the price target from $32 to $36.

Guggenheim Maintains Buy on Life Time Group Hldgs, Raises Price Target to $36

Canaccord Genuity analyst George Gianarikas maintains Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>) with a Buy and lowers the price target from $1.5 to $1.

Canaccord Genuity Maintains Buy on Wallbox, Lowers Price Target to $1

Bloom Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) reported its fourth-quarter <a href="https://www.benzinga.com/news/earnings/25/02/44029264/bloom-energy-stock-is-surging-whats-going-on">results Thursday ahead of expectations</a>.
There is upside potential for the company's revenues from rising power demand, according to JPMorgan.
The Bloom Energy Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781de5064ed0001730076/mark-strouse">Mark Strouse</a> maintained a Neutral rating for Bloom Energy, while raising the price target from $16 to $18.
The Bloom Energy Thesis: The company reported its revenue and pro forma EBITDA at $572 million and $147 million, respectively, beating Street expectations of $538 million and $105 million, Strouse said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Bloom Energy delivered a gross margin beat "driven by favorable operating leverage from larger than expected revenues during the quarter," he added.
While headline product backlog was flat year-on-year, "management noted that backlog is becoming less relevant as the majority of FY24 revenue was booked and shipped intra-year," the analyst wrote.
The company's full-year guidance of revenue, pro forma operating income and gross margins of $1.65 billion to $1.85 billion, $135 million to 165 million and around 29% came above expectations.
Bloom Energy's EBITDA margin profile "is below average for product companies within our coverage," he further stated.
BE Price Action: Shares of Bloom Energy had risen by 0.56% to $23.17 at the time of publication on Friday.
Read More: <a href="https://www.benzinga.com/25/02/43931639/riot-platforms-ceo-reaffirms-plan-to-boost-bitcoin-yield-but-not-looking-too-closely-at-strategys-maneuvers">&nbsp;Bloom Energy Strengthens 10-Year Equinix Partnership, Deploying Next-Gen Fuel Cells For Data Center Power</a>
Photo: Shutterstock

Analyst Color

Earnings Beats

Reiteration

Bloom Energy Posts Q4 Beat: Margin Profile Remains Below Industry Average, Analyst Says

Guggenheim analyst Curry Baker maintains Nexstar Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) with a Buy and raises the price target from $210 to $220.

NXST

Guggenheim Maintains Buy on Nexstar Media Gr, Raises Price Target to $220

Labcorp Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) short percent of float has fallen 3.63% since its last report. The company recently reported that it has 1.83 million shares sold short, which is 2.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Labcorp Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740758442_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Labcorp Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Labcorp Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Labcorp Hldgs's peer group average for short interest as a percentage of float is 9.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Laboratory Corporation Of America Holdings

Is the Market Bullish or Bearish on Labcorp Hldgs?

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has fallen 4.72% since its last report. The company recently reported that it has 7.07 million shares sold short, which is 4.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740758436_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 3.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Zimmer Biomet Holdings?

Lucid Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NYSE">LCID</a>) short percent of float has risen 6.99% since its last report. The company recently reported that it has 271.05 million shares sold short, which is 16.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Lucid Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740758430_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lucid Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lucid Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Lucid Group's peer group average for short interest as a percentage of float is 8.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LCID

Looking Into Lucid Group's Recent Short Interest

Citizens Capital Markets analyst Constantine Davides maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Market Outperform and raises the price target from $26 to $29.

PRVA

Citizens Capital Markets Maintains Market Outperform on Privia Health Gr, Raises Price Target to $29

Options

Iamgold Option Alert: Jun 20 $6 Calls Sweep (5) Near The Ask: 3500 @ $0.518 vs 1609 OI; Ref=$5.4699

Citizens Capital Markets analyst Mitch Germain maintains Plymouth Industrial REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) with a Market Outperform and lowers the price target from $27 to $24.

PLYM

Citizens Capital Markets Maintains Market Outperform on Plymouth Industrial REIT, Lowers Price Target to $24

CLSK

CleanSpark Option Alert: Apr 17 $15 Calls At The Ask: 5000 @ $0.15 vs 880 OI; Ref=$8.0514

Canaccord Genuity analyst Richard Close maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Buy and raises the price target from $29 to $30.

Canaccord Genuity Maintains Buy on Privia Health Gr, Raises Price Target to $30

Citizens Capital Markets analyst Matthew Carletti maintains BeOne Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) with a Market Outperform and raises the price target from $288 to $348.

Citizens Capital Markets Maintains Market Outperform on BeOne Medicines, Raises Price Target to $348

Polestar Automotive Holding Uk Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) has <a href="https://www.benzinga.com/pressreleases/25/02/b44038615/polestar-secures-usd-450-million-term-facility-and-renews-eur-480-million-green-trade-finance-faci">obtained further financial backing</a>, underscoring its focus on growth and long-term sustainability. 
The company has finalized a 12-month term facility of up to $450 million and renewed its 480 million Euros ($499.60 million) Green Trade Finance Facility (TFF). 
This comes after securing more than $800 million in term facilities in December 2024, enhancing its financial position even further.
Polestar also plans to announce global retail sales volumes for first-quarter 2025 on April 10, 2025. 
The company intends to release its full-year and fourth-quarter results for 2024 ahead of or simultaneously with its Annual Report filing on Form 20-F in April 2025.
Also Read: <a href="https://www.benzinga.com/markets/equities/25/02/44041348/werides-robobus-rolls-out-in-france-with-renault-beti-backing-details">WeRide&#8217;s Robobus Rolls Out In France With Renault &amp; Beti Backing: Details</a>
The company had originally planned to release its postponed fourth-quarter results in March, reported Reuters.
For the third-quarter, Polestar saw a <a href="https://www.benzinga.com/25/01/43032533/polestar-stock-skids-after-weak-q3-revenue-but-ceo-projects-2025-to-be-the-strongest-year-ever">10% year-over-year decrease in revenue</a>, dropping to $550.7 million, primarily due to reduced volume and market conditions. Retail sales totaled 12,548 vehicles, marking an 8% decline compared to the previous year.
It also reported a net loss of $323 million, while its adjusted EBITDA loss improved by 28%, reaching $180 million, thanks to cost-cutting measures.
The company said lower-than-expected Polestar 3 and 4 sales, inventory adjustments and market discounting impacted fourth-quarter performance.
In order to attract Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) customers who have harbored <a href="https://www.benzinga.com/tech/25/02/43933726/polestar-attempts-to-woo-disgruntled-tesla-owners-with-offers-2025-to-be-strongest-year-in-polestars-history">negative sentiments about Musk&#8217;s involvement</a> in politics, Polestar is providing up to $20,000 to Tesla vehicle owners who decide to switch and lease a Polestar 3. 
Price Action: PSNY shares are trading lower by 3.15% at $1.08 at last check Friday.
Read Next: <a href="https://www.benzinga.com/markets/equities/25/02/44018649/spacex-rocket-launches-intuitive-machines-athena-lander-details">SpaceX Rocket Launches Intuitive Machines&#8217; Athena Lander: Details</a>
Photo: Shutterstock

PSNY

TSLA

Polestar Secures New $450M Financing Deal To Boost Growth

WIIM

ADGM

Adagio Medical shares are trading lower after the company announced a reduction in workforce in a strategic restructuring.

Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Hold and raises the price target from $17 to $23.

PGNY

Canaccord Genuity Maintains Hold on Progyny, Raises Price Target to $23

Management

Press Releases

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Health Care

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Comments

Medicus Pharma

Medicus Pharma (MDCX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga